Item 7.01 Regulation FD Disclosure

Lpath, Inc. (the "Company") hosted a conference call on June 4, 2009 at 4:30p.m. Eastern time (1:30 p.m. Pacific time), to provide a business review and clinical update. Callers can access a telephone replay of the call until June 14, 2009 by dialing the following numbers (no passcode is required):

Toll-free replay number: 1-800-374-1375

International replay number: 1-402-220-0682

The information in this Item only, is furnished pursuant to Item 7.01 of this Form 8-K. Consequently, it is not deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references this Form 8-K.

Item 8.01 Other Events

The Company announced that it received a grant of up to $3 million over a 3-year period from the National Cancer Institute for the development of the Company's cancer drug candidate ASONEP. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

Exhibits

99.1 Press Release dated June 4, 2009.

---